CD4 and white blood cell declines caused by islatravir are dose-related and reversible, but rule out using it for prevention
The paediatric drug pipeline should include improvements to current HIV treatment, long-acting formulations and antibodies
Merck restarts islatravir HIV treatment studies, but abandons monthly PrEP
European Commission approves first twice-yearly HIV medication
Long-acting cabotegravir and rilpivirine may be feasible for people without viral suppression
Top 5 HIV treatment stories from CROI 2022
Top 5 HIV cure and vaccine stories from CROI 2022
Broadly neutralising antibody treatment: is pre-existing resistance its Achilles heel?
Lenacapavir shows continued promise for first-line treatment and highly resistant HIV
